使用天然颜料 6,6'-二溴靛蓝 ( 6-BrIG ) 作为活性通道制造了双极有机光电晶体管。这些光电晶体管在光照射下产生显着增强的电流,n沟道的光响应度和外部量子效率分别高达10.3 AW -1和2437%,p沟道的光响应度和外部量子效率分别高达55.4 mA W -1和13.1%。此外,通过集成两个双极光电晶体管制作了简单的逆变器互补电路。通道电流取决于光强度和电压偏置。这项研究为深入了解6-BrIG的光电特性奠定了基础,并将该材料介绍为光电应用的环保候选材料。
[EN] INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE<br/>[FR] COMPOSES DE TYPE INDIRUBINE, COMPOSITIONS ET LEURS PROCEDES D'UTILISATION
申请人:UNIV ROCKEFELLER
公开号:WO2005041954A1
公开(公告)日:2005-05-12
Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.
Indirubin and itsderivatives have been reported to exhibit anti-cancer and anti-inflammatory activities. Recently, some of its derived analogs have been shown to have neuroprotective potential. Endoplasmic reticulum (ER) stress has been demonstrated to contribute to the pathogenesis of various neurodegenerative diseases, whereas the effects of indirubin derivatives on ER stress-induced cell death
The synthesis of halogenoindirubins was attempted. The reaction of 3-acetoxy-6-bromoindole () with 6-bromoisation () in methanol with Na2CO3 produced 6-bromo-6′-fluoroindirubin () in 80% yield. Its structure determination was mainly undertaken using 1H NMR spectroscopy. A similar reaction gave 6′-bromoindirubin () and 6-bromoindirubin () in moderate yields. J. Heterocyclic Chem., (2009).
尝试了卤代靛玉红的合成。的反应3-乙酰氧基-6-溴吲哚()与6溴化反应()在甲醇中用Na 2 CO 3生成6-溴-6'-氟代靛红(),产率为80%。其结构确定主要使用1 H NMR光谱进行。类似的反应产生了6'-溴二氢丁香红素()和6-溴二尿红素()以中等的收益率。J.杂环化学,(2009)。
Indirubin-Type Compounds, Compositions, and Methods for Their Use
申请人:Meijer Laurent
公开号:US20070276025A1
公开(公告)日:2007-11-29
Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.
[EN] COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
申请人:ASTRAZENECA AB
公开号:WO2022069520A1
公开(公告)日:2022-04-07
The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where A, Z, Y, RA, Linker and v have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in the prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.